Biotech and Pharmaceuticals Biotechnology

More

  • Price controls on biotech do not work: Pro Tuesday, 29 Sep 2015 | 2:50 PM ET
    Price controls on biotech do not work: Pro

    Biotech's have had a very bad week, but the IBB has recovered a bit today. What's behind all the volatility, with Fed Hassan, Warburg Pincus, and CNBC's Meg Tirrell.

  • LONDON, Sept 29- The first patient has been treated in Britain in a pioneering trial of a new treatment co-developed by Pfizer and derived from embryonic stem cells designed for patients with a condition that can cause blindness. Specialists at London's Moorfields Eye Hospital said the operation, described as "successful", was the first of 10 planned for...

  • Biotech blues: political noise or correction? Monday, 28 Sep 2015 | 5:54 PM ET
    Biotech pharma

    With the biotechnology sector tumbling, is this temporary? Or the beginning of a downward slide? Analysts weigh in.

  • Step away from biotechs, let dust settle: Pro Monday, 28 Sep 2015 | 2:04 PM ET
    Step away from biotechs, let dust settle: Pro

    David Seaburg, Cowen & Company, Jerry Castellini, CastleArk Management, discuss the biotech sector as the IBB heads into bear market territory.

  • IBB enters bear territory Friday, 25 Sep 2015 | 2:53 PM ET
    IBB enters bear territory

    The IBB, biotech ETF has officially entered bear market territory, and has fallen below the level where it was after the flash crash. CNBC's Brian Sullivan and Melissa Lee discuss.

  • Could Spark cure blindness? Thursday, 24 Sep 2015 | 5:51 PM ET
    Could Spark cure blindness?

    CNBC's Meg Tirrell looks at events in biotech that could help the sector out of it's recent struggles. The Fast Money traders discuss the trade.

  • Turing CEO: Will lower drug price ... eventually Tuesday, 22 Sep 2015 | 6:34 PM ET
    Turing CEO: Will lower drug price ... eventually

    NBC News' Andrea Mitchell reports Turing Pharmaceuticals CEO Martin Shkreli will lower the price of Daraprim, which was raised 5,000 percent over the weekend. He says it will happen in the next few weeks.

  • Sept 22- A company formed by genome pioneer Craig Venter will offer clients of a South Africa- based insurance company whole exome sequencing- sequencing all protein-making genes in the human genome- at a price that marks yet another dramatic decline in the cost of gene sequencing, the two companies said on Tuesday. Venter's company, Human Longevity Inc, will...

  • TB drug price cut—but still twice original cost Monday, 21 Sep 2015 | 9:23 PM ET

    A huge overnight price increase for an important tuberculosis drug has been rescinded after a public outcry, the NYT reports.

  • Neurocrine crushes the IBB Friday, 18 Sep 2015 | 2:41 PM ET
    Neurocrine crushes the IBB

    Kevin Gorman, Ph. D., President, CEO, Neurocrine Biosciences, explains how his company is up 144 percent so far this year.

  • Can biofuels replace oil in the future? Wednesday, 9 Sep 2015 | 11:40 AM ET
    Can biofuels replace oil in the future?

    Peder Holk Nielsen, CEO of Novozymes, says it has become tougher for renewables and biofuels to compete with fossil fuels.

  • Short sellers keep sights trained on this sector Friday, 4 Sep 2015 | 10:07 AM ET
    Biotech pharmaceuticals

    Short sellers are continuing to target biotechnology stocks as one of the frothiest sectors in US equities staggers after a bruising August.

  • First biosimilar hits US Thursday, 3 Sep 2015 | 2:59 PM ET
    First biosimilar hits US

    CNBC's Meg Tirrell reports on what could be a new era for U.S. medicine.

  • Health care mergers and acquisitions set to continue Thursday, 3 Sep 2015 | 5:50 AM ET
    Health care mergers and acquisitions set to continue

    Fred Hassan, managing director of healthcare and consumer for Warburg Pincus, says we will see more M&A in the health care sector.

  • Aug 31- Asterias Biotherapeutics Inc said initial data from a small study showed that its lead stem cell therapy could improve mobility in patients paralyzed by a spinal cord injury. Shares of BioTime Inc, a company that owns nearly 70 percent of Asterias, were little changed at $3.07. Asterias bought OPC-1 in 2013 from the erstwhile stem cell research leader...

  • Asterias's stem cell therapy shows promise in study Monday, 31 Aug 2015 | 7:09 AM ET

    Aug 31- Asterias Biotherapeutics Inc said initial data from a small study showed that its lead stem cell therapy could improve mobility in patients paralyzed by a spinal cord injury. Asterias bought OPC-1 in 2013 from the erstwhile stem cell research leader Geron Corp, which decided to focus on developing cancer drugs. Asterias is looking to show recovery of...

  • Biotechs rally back Monday, 24 Aug 2015 | 2:25 PM ET
    Biotechs rally back

    Discussing which biotechs may have been oversold in the selloff, with Michael Yee, RBC Capital biotech analyst.

  • Aug 21- The chief executive officer of biotechnology company Northwest Biotherapeutics Inc said on Friday the company has temporarily stopped screening new patients for the late-stage trial of its experimental brain cancer drug. The study, among patients with newly diagnosed brain cancer, is being conducted in Germany, the United Kingdom, the United States...

  • Time for biotech to bounce back? Monday, 17 Aug 2015 | 2:35 PM ET
    Time for biotech to bounce back?

    David Seaburg, Cowen & Company, and Craig Johnson, Piper Jaffray & Co, discuss biotech, a formerly hot sector that's down more than 7 percent in a month.

  • Bass's biotech beef Wednesday, 12 Aug 2015 | 5:15 PM ET
    Bass's biotech beef

    One biotech stock could see massive moves later this month, thanks to the meddling of hedge fund heavy hitter, Kyle Bass. CNBC's Meg Tirrell reports the latest.